By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.

OK

Takeda Dissident Shareholders Look to Domestic Institutions to Try to Block Shire Deal

The group of Takeda minority shareholders known as Thinking about Takeda’s Bright Future (TTBF) is focusing all its efforts on talking to domestic institutions such as life insurance companies into voting against the acquisition of Shire featured

Strong Demand Likely for Shire/Takeda Divestiture of SHP647

On October 26 Takeda announced it had proposed a remedy to the European Commission of selling Shire’s SHP647, a pipeline compound for the treatment of inflammatory bowel disease, which will potentially compete with Takeda’s marketedfeatured

Takeda to Meet with EC this Week on Shire Review

Takeda expects to hear from the European Commission by the end of the week regarding potential concerns the commission might have with Takeda’s acquisition of Shire, a source close to the situation told CTFN.featured

High Likelihood Takeda Shareholders Back Shire Merger

Chances that the group of Takeda minority shareholders opposing the Japanese drug maker’s planned acquisition of rival Shire will succeed in blocking the deal appear to be low, local sources told CTFN.featured

Updated: EC Filing for Shire/Takeda Merger Made Today

Updated at 12:25pm While CTFN originally expected Takeda to miss the end of September deadline for its EC filing by a few days, Takeda today filed with the EC its merger with Shire with a provisional deadline of November 6, 2018.featured

Takeda Mulls Post-Merger Divestment of Shires Unprofitable Businesses

Japanese drugmaker Takeda is considering selling some of Shire’s divisions once it finalizes its takeover of the Irish peer.featured

Takeda Dissident Shareholders Raise Concerns over Shire Pipeline

A group of minority shareholders of Japanese drug company Takeda will carry out a review of Shire’s R&D pipeline to prove that even the most promising business areas wouldfeatured

Three Essentials from CTFN This Week

A group of 130 shareholders consisting of founding family members and former employees of Japanese drug maker Takeda Pharmaceutical is trying to win support from institutional investorsfeatured

Takeda Dissident Shareholders Hope for Support from Life Insurance Companies

A group of 130 shareholders consisting of founding family members and former employees of Japanese drug maker Takeda Pharmaceutical is trying to win support from institutionalfeatured

Securing Funds Not Seen as an Issue for Takeda Merger With Shire

Japanese pharmaceutical player Takeda should not face issues securing funds for a potential deal with Dublin-headquartered peer Shire, a Tokyo-based M&A lawyer who in the past advised targets acquired by Takeda, told CTFN.featured

X

Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.